Table I.
Patient and study characteristics.
| Authors | Year | Country | Study design | Patient enrollment | Blinding status | No. of patients | Mean/median age, years (range) | Tumor location | TNM stage(s) | Reviewers (experience) | Radiotherapy regimen | Chemotherapy regimen | (Refs.) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xiao-ping et al | 2016 | China | Prospective | Consecutive | Blind | 50 | 48.9±11.1 | Nasopharynx | T2-4N0-3M0-1 | Two radiologists (5 and 20 years) | 7,000–7,600 cGy/30-33 f | TN, TNF, NF | (10) |
| Scalco et al | 2016 | Italy | Retrospective | NA | NA | 30 | NA | HNSCCa | T1-4N1-3 | One radiologist (15 years) | 7,000 cGy/33 f | Cisplatin | (11) |
| Hou et al | 2016 | China | Prospective | Consecutive | Blind | 43 | 49.0 (26–68) | Nasopharynx | T2-4N0-3M0 | Two radiologists (>10 years) | 7,000–7,600 cGy/30-33 f | TN | (12) |
| Hong et al | 2013 | China | Prospective | NA | NA | 134 | 47.0 (18–79) | Nasopharynx | T1-4 | NA | 6,600–7,875f cGy/30-33 | TP, cisplatin | (14) |
| King et al | 2013 | China | Prospective | Consecutive | NA | 37 | 57.0 (45–71) | HNSCCb | III–IV | One radiologist (>15 years) | NA | NA | (13) |
| Nakajo et al | 2012 | Japan | Retrospective | NA | NA | 26 | 65.0 (45–89) | HNSCCc | T1-4N0-3 | NA | 6,000 cGy/30 f | NA | (15) |
| Hatakenaka et al | 2011 | Japan | Retrospective | NA | Blind | 38 | 64.0 (37–85) | HNSCCd | T1-4N0-3 | Two radiologists (unknown) | 6,000 cGy | S-1, cisplatin | (8) |
| Vandecaveye et al | 2010 | Belgium | Prospective | Consecutive | Blind | 30 | 53.0 (38–66) | HNSCCe | T1-4N1-3 | One radiologist (6 years) | 7,200 cGy | NA | (16) |
| Kim et al | 2009 | USA | Prospective | NA | NA | 33 | 61.0±10.8 | HNSCCf | T0-4N1-2bM0 | NA | 7,040 cGy/32 f | Cisplatin | (7) |
a
Oropharynx, nasopharynx, hypopharynx, larynx, and unknown primary.
b
Oropharynx, hypopharynx, larynx, nasal cavity, oral cavity, and maxillary sinus.
c
Oropharynx, nasopharynx, hypopharynx, larynx, oral cavity and maxillary sinus.
d
Oropharynx, hypopharynx, larynx and oral cavity.
e
Oropharynx, tonsil, base of tongue, supraglottic, glottic and piriform sinus.
f
Larynx, vallecula, tonsil, base of tongue and unknown primary. NA, not available; HNSCC, head and neck squamous cell carcinoma; TN, Taxol + nedaplatin; TNF, Taxol + nedaplatin + 5-fluorouracil; NF, nedaplatin + 5-fluorouracil; TP, Taxol + cisplatin.